An open-label, 2-cohort, fixed-sequence, drug-drug interaction study of PCN-101 in healthy adult subjects
Latest Information Update: 20 Aug 2022
Price :
$35 *
At a glance
- Drugs Arketamine (Primary)
- Indications Depressive disorders
- Focus Pharmacokinetics
- Sponsors ATAI Life Sciences
- 15 Aug 2022 Status changed from recruiting to completed, according to an ATAI Life Sciences media release.
- 01 Apr 2022 Status changed from planning to recruiting as per to an ATAI Life Sciences media release.
- 19 Jan 2022 New trial record